YK11 |
Katalog-Nr.GC31442
One-Click Copy Product Info
|
YK11 ist ein partieller Agonist des Androgenrezeptors mit osteogener AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1370003-76-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
YK11 is a partial agonist of androgen receptor, with osteogenic activity.
YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM or 500 nM)[1]. YK11 (0.5 µM) increases the cell growth of osteoblastic MC3T3-E1 cells, and enhances ALP activity via AR. YK11 also elevates osteoprotegerin mRNA expression (0.5 µM) and dose-dependently increases osteocalcin mRNA expression (0.1-1.0 µM). In addition, YK11 enhances phosphorylation of Akt protein via rapid non-genomic signaling[2].
[1]. Kanno Y, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460-5. [2]. Yatsu T, et al. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. Biol Pharm Bull. 2018;41(3):394-398.
|
Cell experiment: |
Mouse myoblast C2C12 cells are cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere with 5% CO2. C2C12 cells are seeded on plates and maintained in culture medium for 24 h. To induce myogenic differentiation, YK11 or DHT in DMEM supplemented with 2% horse serum (differentiation medium) is added to the cells on day 0. For the neutralization assay of Fst (also known as activin-binding protein), C2C12 cells are maintained in differentiation medium in the presence of anti-Fst antibody[1]. |
|
References: [1]. Kanno Y, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460-5. |
|
| Cas No. | 1370003-76-1 | SDF | |
| Canonical SMILES | O=C1CCC2C(CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(OC(C)(OC)O/5)C5=C/C(OC)=O)=C1 | ||
| Formula | C25H34O6 | M.Wt | 430.53 |
| Löslichkeit | DMSO : ≥ 64 mg/mL (148.65 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3227 mL | 11.6136 mL | 23.2272 mL |
| 5 mM | 464.5 μL | 2.3227 mL | 4.6454 mL |
| 10 mM | 232.3 μL | 1.1614 mL | 2.3227 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)